BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29225164)

  • 1. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study.
    Kharfan-Dabaja MA; Raj R; Nikolaenko L; Ahmed S; Reddy N; Nathan S; Cherry M; El-Jurdi N; Obiozor C; Fenske TS; Song J; Muzzafar T; Ayala E; Savani B; Khawandanah M; Caimi PF; Hamadani M; Forman SJ; Hussaini M; de Lima M; Olteanu H; Shah B; Chavez JC; Al Malki M; Kumar A; Ganguly S
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):486-493. PubMed ID: 29225164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis.
    El-Asmar J; Reljic T; Ayala E; Hamadani M; Nishihori T; Kumar A; Kharfan-Dabaja MA
    Biol Blood Marrow Transplant; 2016 May; 22(5):802-14. PubMed ID: 26713431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.
    Moustafa MA; Ramdial JL; Tsalatsanis A; Khimani F; Dholaria B; Bojanini L; Brooks T; Zain J; Bennani NN; Braunstein Z; Brammer JE; Beitinjaneh A; Jagadeesh D; Weng WK; Kumar A; Kharfan-Dabaja MA; Ahmed S; Murthy HS
    Transplant Cell Ther; 2024 May; 30(5):516.e1-516.e10. PubMed ID: 38431075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
    Epperla N; Fenske TS; Lazarus HM; Hamadani M
    Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
    Dahi PB; Tamari R; Devlin SM; Maloy M; Bhatt V; Scordo M; Goldberg J; Zelenetz AD; Hamlin PA; Matasar MJ; Maragulia J; Giralt SA; Perales MA; Moskowitz CH; Sauter CS
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2004-9. PubMed ID: 25175794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
    Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma.
    Mirza AS; Dholaria BR; Hussaini M; Mushtaq S; Horna P; Ravindran A; Kumar A; Ayala E; Kharfan-Dabaja MA; Bello C; Chavez JC; Sokol L
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e513-e520. PubMed ID: 31253594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
    Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS
    Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
    Htut M; D'Souza A; Krishnan A; Bruno B; Zhang MJ; Fei M; Diaz MA; Copelan E; Ganguly S; Hamadani M; Kharfan-Dabaja M; Lazarus H; Lee C; Meehan K; Nishihori T; Saad A; Seo S; Ramanathan M; Usmani SZ; Gasparetto C; Mark TM; Nieto Y; Hari P
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):478-485. PubMed ID: 29079457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review.
    Reljic T; Kumar A; Djulbegovic B; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2015 Aug; 50(8):1069-74. PubMed ID: 25867647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center.
    Huang H; Jiang Y; Wang Q; Guo L; Jin Z; Fu Z; Han Y; Sun A; Liu W; Ruan J; Wu D
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1393-1397. PubMed ID: 28478121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation.
    Kapke JT; Epperla N; Shah N; Richardson K; Carrum G; Hari PN; Pingali SR; Hamadani M; Karmali R; Fenske TS
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):408-414. PubMed ID: 28756899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
    Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
    Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
    Bachanova V; Burns LJ; Ahn KW; Laport GG; Akpek G; Kharfan-Dabaja MA; Nishihori T; Agura E; Armand P; Jaglowski SM; Cairo MS; Cashen AF; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Ghosh N; Holmberg LA; Inwards DJ; Kanate AS; Lazarus HM; Malone AK; Munker R; Mussetti A; Norkin M; Prestidge TD; Rowe JM; Satwani P; Siddiqi T; Stiff PJ; William BM; Wirk B; Maloney DG; Smith SM; Sureda AM; Carreras J; Hamadani M;
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1605-11. PubMed ID: 25983043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
    Yamasaki S; Suzuki R; Hatano K; Fukushima K; Iida H; Morishima S; Suehiro Y; Fukuda T; Uchida N; Uchiyama H; Ikeda H; Yokota A; Tsukasaki K; Yamaguchi H; Kuroda J; Nakamae H; Adachi Y; Matsuoka KI; Nakamura Y; Atsuta Y; Suzumiya J
    Bone Marrow Transplant; 2017 Jul; 52(7):969-976. PubMed ID: 28368379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
    Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.